NHLBI Funding & Research Opportunities and Announcements for May 1, 2020

Funding and Research Opportunities The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:              General Notices   The National Institutes of Health (NIH) Sexual & Gender Minority Research Office (SGMRO) Announces Webinar on Navigating the NIH for Researchers Interested in DSD and Intersex Populations (NOT-OD-20-102) Office of the Director, NIH Notice of Changes to Funding Opportunities  Notice of Change in Application Due Date for RFA-HL-21-011, Stimulating T4 Implementation Research to Optimize Integration of Proven-effective Interventions for HLB Diseases and Sleep Disorders into Practice (STIMULATE-2) (R61/R33 Clinical Trial Required) (NOT-HL-20-783) National Heart, Lung, and Blood Institute Notices of Special Interest Notice of Special Interest (NOSI): Heart, lung, blood and sleep focused ancillary studies to large ongoing clinical trials (NOT-HL-20-755) National Heart, Lung, and Blood Institute Notice of Special Interest (NOSI): Pulmonary Complications of Hematopoietic Stem Cell Transplantation in Childhood (NOT-HL-20-761)National Heart, Lung, and Blood Institute Eunice Kennedy Shriver National Institute of Child Health and Human Development Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions on Coronavirus Disease 2019 (COVID-19) for Currently Active NHLBI Phase I-III Clinical Trials (NOT-HL-20-782) National Heart, Lung, and Blood Institute Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-RM-20-015) Office of Strategic Coordination (Common Fund) Funding Opportunities  Limited Competition: Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC) Disease Modifying Therapies for Chronic Lung Diseases (U24 Clinical Trial Required - Infrastructure) (RFA-HL-21-012) National Heart, Lung, and Blood Institute Application Receipt Date(s): July 24, 2020 by 5:00 PM local time of applicant organization. Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required) (RFA-HL-21-013) National Heart, Lung, and Blood Institute Application Receipt Date(s): 07/24/2020, 06/01/2021, 06/01/2022